NCT03632733

Brief Summary

It had been found in certain studies that there is an alteration of normal skin flora in patients with arsenical keratosis. The relationship between such altered skin flora and development of keratosis in arsenicosis is not established or explored.There is no such study where effects of antimicrobials have been evaluated as the treatment of arsenical keratosis. So the present study is designed to see the effects of antimicrobials on the altered skin flora (Enterobacter and Aspergillus) in patients with palmar arsenical keratosis.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
30

participants targeted

Target at P25-P50 for phase_2

Timeline
Completed

Started Jan 2018

Shorter than P25 for phase_2

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 21, 2018

Completed
7 months until next milestone

First Submitted

Initial submission to the registry

August 13, 2018

Completed
2 days until next milestone

First Posted

Study publicly available on registry

August 15, 2018

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 30, 2018

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2018

Completed
Last Updated

August 17, 2018

Status Verified

August 1, 2018

Enrollment Period

9 months

First QC Date

August 13, 2018

Last Update Submit

August 15, 2018

Conditions

Outcome Measures

Primary Outcomes (1)

  • Changes in keratotic nodular size

    palmar arsenical keratosis will be measured before and after applying interventions

    three months

Study Arms (4)

Tetracycline group

ACTIVE COMPARATOR

Tetracycline cream twice daily for three months

Drug: Tetracycline

Clotrimazole group

ACTIVE COMPARATOR

Clotrimazole cream twice daily for three months

Drug: Clotrimazole

Combination drug group

ACTIVE COMPARATOR

Tetracycline and Clotrimazole combination cream twice daily for three months

Drug: Tetracycline and Clotrimazole

Placebo group

PLACEBO COMPARATOR

participants will be provided a cream containing no active drug ingredients

Other: Placebo

Interventions

Tetracycline cream

Also known as: Tetrax
Tetracycline group

Clotrimazole cream

Also known as: Clotrim
Clotrimazole group

Combination cream

Also known as: No other name
Combination drug group
PlaceboOTHER

Placebo cream without active drug ingredients

Also known as: No other name
Placebo group

Eligibility Criteria

Age18 Years - 60 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Drinking arsenic contaminated water (\>50 microgram/ litre) for more than 6 months
  • Patient with moderate to severe arsenical palmar keratosis
  • Patient voluntarily agreed to participate
  • Patient did not receive topical application of any drug for the last three months
  • Patient who understood the instructions of applying drug and could apply drug as per as instructions -

You may not qualify if:

  • Patient who received any treatment of arsenicosis within last three months
  • Patient with diagnosed skin diseases, like- atopic dermatitis and psoriasis
  • Any diagnosed systemic diseases, inflammatory disease and infectious condition that affect the skin, for example- diabetes melitus, SLE and hepatitis

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Eruain Community Clinic

Lākshām, 3570, Bangladesh

RECRUITING

MeSH Terms

Interventions

TetracyclineClotrimazole

Intervention Hierarchy (Ancestors)

TetracyclinesNaphthacenesPolycyclic Aromatic HydrocarbonsHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbonsOrganic ChemicalsPolycyclic CompoundsImidazolesAzolesHeterocyclic Compounds, 1-RingHeterocyclic Compounds

Study Officials

  • Asiya Ferdous, MBBS

    Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Asiya Ferdous, MBBS

CONTACT

Wasi Azam, MBA

CONTACT

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Masking Details
Participants are not aware of the drug they are given
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Three antimicrobials ( two single and one in combination form) and a placebo will be provided in patients randomly
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Resident, Department of Pharmacology, BSMMU

Study Record Dates

First Submitted

August 13, 2018

First Posted

August 15, 2018

Study Start

January 21, 2018

Primary Completion

October 30, 2018

Study Completion

December 31, 2018

Last Updated

August 17, 2018

Record last verified: 2018-08

Locations